Frontage Holdings Corp represents values of innovation, excellence, and client-centricity. With a strong corporate philosophy, the company strives for continuous growth by providing exceptional services and solutions in the healthcare and pharmaceutical industries. Frontage Holdings Corp is committed to delivering high-quality results and meeting clients' needs through cutting-edge technology, extensive expertise, and a dedicated team. As a trusted partner, Frontage Holdings Corp consistently aims to exceed expectations, foster long-term relationships, and contribute to the advancement of global healthcare.

Frontage Holdings Corp is primarily present in China and the United States.

Frontage Holdings Corp has achieved several significant milestones in its history. The company successfully went public in [year], marking a major achievement in its growth trajectory. Additionally, Frontage Holdings Corp expanded its operations and now operates in [number] countries, further enhancing its global presence. The company has also made notable advancements in [specific field/industry], consolidating its position as a leader in this area. Frontage Holdings Corp has continually demonstrated its commitment to innovation, consistently releasing cutting-edge products and services. These accomplishments have solidified the company's reputation as a top player in the market and have contributed to its continued success.

Frontage Holdings Corp is a leading provider of pharmaceutical R&D services in China. Established in 2014, it has rapidly grown to become a trusted partner for global pharmaceutical and biotech companies. Frontage offers a comprehensive range of services, including preclinical and clinical research, bioanalysis, data management, and regulatory support. With state-of-the-art facilities and a team of experienced scientists, Frontage delivers high-quality solutions to accelerate drug development. The company's commitment to innovative research and customer satisfaction has earned it a strong reputation in the industry. Frontage Holdings Corp continues to drive advancements in pharmaceutical sciences, contributing to improving global healthcare outcomes.

The main competitors of Frontage Holdings Corp in the market include Covance Inc., Charles River Laboratories International, Inc., and WuXi AppTec Holdings Inc.

Frontage Holdings Corp is primarily active in the Contract Research Organization (CRO) industry. As a leading provider of integrated pharmaceutical R&D services, Frontage Holdings Corp offers a comprehensive range of solutions to support drug discovery and development. With a focus on bioanalytical, preclinical, and clinical research services, the company plays a vital role in advancing healthcare and pharmaceutical innovations. Through its expertise and extensive network, Frontage Holdings Corp serves clients across various sectors, including pharmaceuticals, biotechnology, and medical device companies.

Frontage Holdings Corp is a publicly traded company renowned for its business focus on providing integrated drug development solutions to pharmaceutical, biotechnology, and medical device companies. As a leading service provider, Frontage offers a comprehensive range of preclinical and clinical research services, including bioanalytical testing, drug metabolism analysis, and early-stage clinical trials. With a dedication to quality and scientific expertise, Frontage endeavors to accelerate the drug development process, enabling clients to bring innovative therapies to market more efficiently. With its robust service offerings and commitment to industry excellence, Frontage Holdings Corp is at the forefront of facilitating advancements in healthcare and the pharmaceutical industry.

Az Frontage Holdings P/E mutatója 8,24.

Az Frontage Holdings KUV 0,67.

Az AlleAktien Minőségi Score Frontage Holdings esetében 3/10.

A várt Frontage Holdings forgalma 297,23 Mió. USD.

A(z) várt Frontage Holdings nyereség 24,23 Mió. USD.

Frontage Holdings Corp is a leading provider of CRO services (Contract Research Organization) specializing in pharmaceutical and medical research, development, and manufacturing in Asia. The company offers a wide range of services including clinical research, preclinical development, pharmaceutical development, and analytics. The Clinical Research Services (CRS) division of Frontage offers a broad range of clinical research services including study conduct, data management, statistical data analysis, and clinical study reporting. Frontage CRS supports companies in drug development from concept to market launch. The Preclinical Development Services (PDS) division focuses on animal studies and preclinical studies. PDS conducts studies to evaluate the safety and efficacy of new drugs, including studying the pharmacokinetic properties of a substance. The Pharmaceutical Development Services (PDS) division of Frontage specializes in drug development, utilizing precision medicine and computer-assisted processes. Frontage offers a wide range of services including drug development and formulation, manufacturing and packaging, as well as quality and compliance. Frontage also offers Analytical Services to help companies monitor and evaluate drugs. The company provides services that assess the purity, efficacy, and safety of products, while also considering quality assurance and compliance. Frontage is a one-stop solution provider for pharmaceutical companies, offering support in product development, registration support, market launch, and commercial support. The goal of Frontage is to provide services that accelerate drug development and improve global health.

A(z) Frontage Holdings évente alkalommal oszt ki 0 USD összegű osztalékot.

A Frontage Holdings esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Frontage Holdings ISIN kódja: KYG3679P1019.

Az Frontage Holdings tőzsdei rövidítése 1521.HK.

Az elmúlt 12 hónapban a(z) Frontage Holdings osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Frontage Holdings várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Frontage Holdings jelenlegi osztalékhozama .

A(z) Frontage Holdings negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Frontage Holdings az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Frontage Holdings a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Frontage Holdings által 2024. 09. 28.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 09. 28.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 09. 28. időpontban történt.

2023 évben a Frontage Holdings 0 USD összegű osztalékot fizetett ki.

Az Frontage Holdings osztalékait USD fizeti ki.